FDA Approval Sends Tonix (TNXP) Into Wild Volatility: What Traders Need to Know
Biotech breakthrough collides with Wall Street uncertainty, sparking huge debate among investors
Tonix Pharmaceuticals’ TNXP, trading on the Nasdaq in the biotechnology sector, just rocked the market with a stunning FDA approval of Tonmya, the first fibromyalgia treatment in over 15 years. The buzz is irresistible—but so is the volatility. Here's why everyone won't stop talking about this.
In a flash, the company’s stock surged 17% after hours, driven by the long-awaited green light for Tonmya, a non-opioid, once-a-day sublingual tablet, poised to ease chronic pain and fatigue for millions. Fibromyalgia affects over 10 million U.S. adults, especially women, and has lacked innovation until now.
But Monday’s open brought a dramatic twist: TNXP retraced sharply—down ~20% intraday, rattling both bullish and risk-averse investors. Despite this, pre-market trading showed renewed optimism, with gains of 4%–12.6% as hopes reignited.
Amid all this, investors are asking: is it a classic “sell the news” moment—or a buying opportunity before Tonmya’s Q4 2025 commercial launch?
Tonix’s cash runway remains a bright spot: about $125.3 million as of June 30, enough to fund operations into Q3 2026. That gives the company time to execute commercialization, but analysts are watching execution and dilution closely.
On the commercial front, Tonmya is being marketed as safer and more effective due to its sublingual delivery, bypassing the liver and avoiding problematic metabolites—geared toward more sustained relief with fewer side effects.
Investor sentiment reflects the tension: some retail traders are “extremely bullish”, while others counsel caution, reminding that “this is a marathon, not a sprint”.
So here's where things stand: TNXP is trending, fueled by an approved therapy that promises to disrupt a $3.8 billion fibromyalgia market. Yet the stock’s sharp swings highlight the uncertainty over execution, particularly around commercialization, fundraising, and earnings ahead of Q3 2025 results.
Let’s keep watching: TNXP might light up again—or test patience. But for now, Tonmya’s approval marks a landmark moment in biotech—and a high-stakes story for investors and patients alike.
Tonix Pharmaceuticals Holding Corp (TNXP) is a equity in the USA market. The price is 40.01 USD currently with a change of -11.34000 (-0.22084%) from the previous close. The intraday high is 62.64 USD and the intraday low is 39.61 USD. The latest open price was 53.51 USD and the intraday volume is 5751841. The latest trade time is Monday, August 18, 16:49:06 UTC.